BLOOD DEHYDROEPIANDROSTERONE-SULFATE (DHEAS) LEVELS IN POLYMYALGIA-RHEUMATICA GIANT-CELL ARTERITIS AND PRIMARY FIBROMYALGIA

Blood levels of dehydroepiandrosterone sulphate (DHEAS) were measured by radioimmunoassay (RIA) in patients with: a) polymyalgia rheumatica/giant cell arteritis (PMR:TA; N = 25), with and without cortisone derivative treatment (N = 10 and N = 15, respectively); and b) primary fibromyalgia (PF; N = 15 The mean DHEAS levels were found to be significantly reduced in PMR: TA, compared to those in PF (Geom. mean 820 vs. 2300 nmol/l, respectively, p < 0.001), and the reduction was more marked in patients on cortisone derivative treatment. The DHEAS levels found in PF were found to be normal and consistent with those previously reported in non-immune mediated rheumatological diseases such as osteoarthritis, and in healthy subjects, using the same method of analysis. The low levels found inpatients with PM. TA are in accordance with those previously reported in immune-mediated diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis, suggesting that diminution of DHEAS is a constant endocrinologic feature in these categories of patients. The pathophysiological significance of these low DHEAS levels needs to be investigated.